PT - JOURNAL ARTICLE AU - Yosuke Hattori AU - Toshihisa Kojima AU - Atsushi Kaneko AU - Daihei Kida AU - Yuji Hirano AU - Takayoshi Fujibayashi AU - Kenya Terabe AU - Yuichiro Yabe AU - Hiroyuki Miyake AU - Takefumi Kato AU - Hideki Takagi AU - Masatoshi Hayashi AU - Takayasu Ito AU - Yasuhide Kanayama AU - Takeshi Oguchi AU - Nobunori Takahashi AU - Hisato Ishikawa AU - Koji Funahashi AU - Naoki Ishiguro TI - Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study AID - 10.3899/jrheum.151006 DP - 2016 Aug 01 TA - The Journal of Rheumatology PG - 1475--1479 VI - 43 IP - 8 4099 - http://www.jrheum.org/content/43/8/1475.short 4100 - http://www.jrheum.org/content/43/8/1475.full SO - J Rheumatol2016 Aug 01; 43 AB - Objective. To evaluate the rates of retention and discontinuation of adalimumab (ADA) due to efficacy and safety in Japanese patients with rheumatoid arthritis (RA).Methods. All patients with RA (n = 476) who were treated with ADA in the Tsurumai Biologics Communication Registry were enrolled.Results. The retention rate of ADA was 46% at 5 years. When focusing on insufficient efficacy, previous biologics use and high baseline disease activity were significant risk factors for up to 1 year. Methotrexate (MTX) use was a significantly low risk factor after 1 year of treatment.Conclusion. Concomitant MTX contributes to the longterm efficacy of ADA therapy.